Sukrit Narula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sukrit Narula has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Celik
Mersin University
1 shared publication - Aldo Pietro Maggioni
Centro Studi ANMCO—Heart Care Foundation, 50121 Florence, Italy
1 shared publication Alex Grinvalds
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
1 shared publication- Ambuj Roy
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, Delhi, India
1 shared publication - Andrzej Budaj
Centre of Postgraduate Medical Education, Department of Cardiology, Grochowski Hospital, Warsaw, Poland
1 shared publication - Ann Le
Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada; Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
Epigenetic signatures of biological vulnerability and residual risk in heart failure
Background: DNA methylation (DNAm) signatures capture cumulative lifestyle exposures and biological aging. This prospective study evaluated whether DNAm-based scores and epigenetic aging clocks are associated with clinical outcomes and mortality in a multinational cohort of patients with heart failure (HF). Methods: We studied 2,594 patients with HF from 40 countries in the Global Congestive Heart Failure (G-CHF) registry with whole-blood DNAm data. Fifteen published DNAm-based scores and epigenetic aging clocks reflecting lifestyle, environmental and physiological exposures, inflammation, frailty, mortality risk, and biological aging were derived. Associations with HF hospitalization, cardiovascular death, and all-cause death were assessed using multivariable Cox regression adjusted for age, sex, ancestry, the MAGGIC risk score, and NT-proBNP. Incremental prognostic value was compared to MAGGIC score and NT-proBNP. Extreme DNAm profiles were defined as scores or clocks exceeding ±1.5 standard deviations (s.d.) from the population mean. Results: Mean age was 62.7±14.0 years, 66.2% were male, and mean left ventricular ejection fraction was 40.1±14.1%. During a median follow-up of 3.0 years, 338 patients were hospitalized for HF, 349 died from cardiovascular causes, and 565 died from any cause. Higher epigenetic age and DNAm scores for CRP, frailty, and mortality were associated with increased risk, whereas higher diet-related DNAm scores were inversely associated. For all-cause death, adjusted hazard ratios per 1-s.d. were 1.36 (95% CI, 1.24-1.50) for GrimAge, 1.27 (95% CI, 1.17-1.38) for the DNAm score for CRP, 1.44 (95% CI, 1.28-1.63) for the DNAm score for frailty, and 1.48 (95% CI, 1.32-1.65) for the DNAm score for mortality, compared with 0.81 (95% CI, 0.75-0.88) and 0.86 (95% CI, 0.79-0.94) for the DNAm scores for Alternative Healthy Eating Index and Mediterranean Diet Score. These patterns were directionally consistent for cardiovascular death and weaker for HF hospitalization and were more pronounced among patients with lower clinical risk (MAGGICinteraction <0.05), particularly for all-cause death. Patients with 4-5 extreme-high DNAm scores or clocks had more than twice the risk of death (HR, 2.27; 95% CI, 1.65-3.13). Conclusions: DNAm-based scores and epigenetic aging clocks reflect multiple dimensions of biological vulnerability in HF and are associated with clinical outcomes and mortality beyond clinical risk factors. Clinical Perspective: What is new?: In 2,594 patients with heart failure (HF) from 40 countries, blood-based DNA methylation (DNAm) scores for inflammation, frailty, and mortality, as well as epigenetic aging measures, were associated with mortality and other clinical outcomes after adjustment for established risk factors and NT-proBNP. These associations were stronger among patients with lower clinical risk, suggesting that epigenetic signatures may capture biological vulnerability not fully reflected by conventional risk assessment. A greater accumulation of adverse epigenetic signatures was associated with progressively higher mortality risk; each additional extreme-high DNAm score or aging clock was associated with an 18% higher risk of death. What are the clinical implications?: DNA methylation may complement conventional clinical risk assessment by identifying biological vulnerability beyond established clinical risk factors. Multidimensional epigenetic profiling may provide a framework for molecular phenotyping of HF and for identifying patients with residual biological risk who may warrant further investigation.
Open AccessEpigenetic signatures of biological vulnerability and residual risk in heart failure
Background: DNA methylation (DNAm) signatures capture cumulative lifestyle exposures and biological aging. This prospective study evaluated whether DNAm-based scores and epigenetic aging clocks are associated with clinical outcomes and mortality in a multinational cohort of patients with heart failure (HF). Methods: We studied 2,594 patients with HF from 40 countries in the Global Congestive Heart Failure (G-CHF) registry with whole-blood DNAm data. Fifteen published DNAm-based scores and epigenetic aging clocks reflecting lifestyle, environmental and physiological exposures, inflammation, frailty, mortality risk, and biological aging were derived. Associations with HF hospitalization, cardiovascular death, and all-cause death were assessed using multivariable Cox regression adjusted for age, sex, ancestry, the MAGGIC risk score, and NT-proBNP. Incremental prognostic value was compared to MAGGIC score and NT-proBNP. Extreme DNAm profiles were defined as scores or clocks exceeding ±1.5 standard deviations (s.d.) from the population mean. Results: Mean age was 62.7±14.0 years, 66.2% were male, and mean left ventricular ejection fraction was 40.1±14.1%. During a median follow-up of 3.0 years, 338 patients were hospitalized for HF, 349 died from cardiovascular causes, and 565 died from any cause. Higher epigenetic age and DNAm scores for CRP, frailty, and mortality were associated with increased risk, whereas higher diet-related DNAm scores were inversely associated. For all-cause death, adjusted hazard ratios per 1-s.d. were 1.36 (95% CI, 1.24-1.50) for GrimAge, 1.27 (95% CI, 1.17-1.38) for the DNAm score for CRP, 1.44 (95% CI, 1.28-1.63) for the DNAm score for frailty, and 1.48 (95% CI, 1.32-1.65) for the DNAm score for mortality, compared with 0.81 (95% CI, 0.75-0.88) and 0.86 (95% CI, 0.79-0.94) for the DNAm scores for Alternative Healthy Eating Index and Mediterranean Diet Score. These patterns were directionally consistent for cardiovascular death and weaker for HF hospitalization and were more pronounced among patients with lower clinical risk (MAGGICinteraction <0.05), particularly for all-cause death. Patients with 4-5 extreme-high DNAm scores or clocks had more than twice the risk of death (HR, 2.27; 95% CI, 1.65-3.13). Conclusions: DNAm-based scores and epigenetic aging clocks reflect multiple dimensions of biological vulnerability in HF and are associated with clinical outcomes and mortality beyond clinical risk factors. Clinical Perspective: What is new?: In 2,594 patients with heart failure (HF) from 40 countries, blood-based DNA methylation (DNAm) scores for inflammation, frailty, and mortality, as well as epigenetic aging measures, were associated with mortality and other clinical outcomes after adjustment for established risk factors and NT-proBNP. These associations were stronger among patients with lower clinical risk, suggesting that epigenetic signatures may capture biological vulnerability not fully reflected by conventional risk assessment. A greater accumulation of adverse epigenetic signatures was associated with progressively higher mortality risk; each additional extreme-high DNAm score or aging clock was associated with an 18% higher risk of death. What are the clinical implications?: DNA methylation may complement conventional clinical risk assessment by identifying biological vulnerability beyond established clinical risk factors. Multidimensional epigenetic profiling may provide a framework for molecular phenotyping of HF and for identifying patients with residual biological risk who may warrant further investigation.
- Open Access
- 10 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0354952
Genetic predisposition to high blood pressure and out-of-office hypertension: Insights from a population sample in liechtenstein
Genetic predisposition is a risk factor for office hypertension. We sought to determine whether genetic predisposition identifies individuals with ambulatory daytime hypertension. 1444 participants from the GAPP study (ages 25–41) were analyzed. We evaluated two measures of predisposition to hypertension: family history and polygenic risk scores (PRS). We evaluated correlation of predisposition with blood pressure traits and compared incremental value of each predisposition measure to a validated ambulatory BP prediction model. 12% of participants had office hypertension, while 37% had out-of-office hypertension. The correlation between PRS and family history of hypertension was low (R 2 = 4.96x10 -3 ), but both were strongly associated with ambulatory blood pressure (2.2 mmHg per 1 SD increase [95% CI: 1.6, 2.7] & 2.4 mmHg increase with positive family history [95% CI: 1.3, 3.4], respectively). PRS provides incremental improvement predicting ambulatory systolic blood pressure beyond a validated blood pressure prediction score (ΔAIC = −33), whereas family history does not (ΔAIC = 1). The difference between a baseline prediction algorithm for identifying ambulatory systolic hypertension (positive likelihood ratio of 6.87 [95% CI: 5.56, 8.49]; negative likelihood ratio of 0.45 [95% CI: 0.39, 0.51]) and the same model with PRS integrated (positive likelihood ratio of 7.69 [95% CI: 6.18, 9.57]; negative likelihood ratio of 0.43 [95% CI: 0.37, 0.49]) was modest. In a white European sample from Liechtenstein, PRS provides incremental information in identification of individuals with ambulatory hypertension, unlike family history. However, these gains are modest and warrant further development to improve predictive utility at the point-of-care.
- 10 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0354952
Open AccessGenetic predisposition to high blood pressure and out-of-office hypertension: Insights from a population sample in liechtenstein
Genetic predisposition is a risk factor for office hypertension. We sought to determine whether genetic predisposition identifies individuals with ambulatory daytime hypertension. 1444 participants from the GAPP study (ages 25–41) were analyzed. We evaluated two measures of predisposition to hypertension: family history and polygenic risk scores (PRS). We evaluated correlation of predisposition with blood pressure traits and compared incremental value of each predisposition measure to a validated ambulatory BP prediction model. 12% of participants had office hypertension, while 37% had out-of-office hypertension. The correlation between PRS and family history of hypertension was low (R 2 = 4.96x10 -3 ), but both were strongly associated with ambulatory blood pressure (2.2 mmHg per 1 SD increase [95% CI: 1.6, 2.7] & 2.4 mmHg increase with positive family history [95% CI: 1.3, 3.4], respectively). PRS provides incremental improvement predicting ambulatory systolic blood pressure beyond a validated blood pressure prediction score (ΔAIC = −33), whereas family history does not (ΔAIC = 1). The difference between a baseline prediction algorithm for identifying ambulatory systolic hypertension (positive likelihood ratio of 6.87 [95% CI: 5.56, 8.49]; negative likelihood ratio of 0.45 [95% CI: 0.39, 0.51]) and the same model with PRS integrated (positive likelihood ratio of 7.69 [95% CI: 6.18, 9.57]; negative likelihood ratio of 0.43 [95% CI: 0.37, 0.49]) was modest. In a white European sample from Liechtenstein, PRS provides incremental information in identification of individuals with ambulatory hypertension, unlike family history. However, these gains are modest and warrant further development to improve predictive utility at the point-of-care.
- Open Access
- 19 June 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
Primary prevention statin eligibility for U.S. adults under the 2026 ACC/AHA dyslipidemia guideline
- 19 June 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
Open AccessPrimary prevention statin eligibility for U.S. adults under the 2026 ACC/AHA dyslipidemia guideline